All In Biotech

Drug Trial Radar · NCT05112159

Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered IPG1094 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

76

Actual

Start

Sep 27, 2021

Primary completion

Jul 25, 2022

Study completion Jul 25, 2022

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • IPG1094 300 mg SADDrug

    a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,300 mg, QD, 3 tablets

  • IPG1094 600 mg SADDrug

    A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days, 600 mg, QD, 6tablets

  • IPG1094 900 mg SADDrug

    A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,900 mg, QD, 9tablets

  • IPG1094 1200 mg SADDrug

    A Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,1200 mg, QD, 12 tablets

  • IPG1094 600 mg MAD QDDrug

    Dosing begins on Day 1 and continues for 10 days with daily doses of 600 mg QD.

  • IPG1094 200 mg MAD BIDDrug

    Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo

  • IPG1094 300 mg MAD BIDDrug

    Dosing starts on Day 1 and extends over a 10-day period. Subjects are discharged on Day 13, with a follow-up 7 days after the last dose, each cohort comprises approximately eight subjects, with 6 subjects on IPG1094 and 2 subjects on placebo

  • IPG1094 300 mg Fed-FastedDrug

    For Cohort FE-2, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fed condition, and Day 5 (anticipated) of Period 2 under fasted condition.

  • IPG1094 300 mg Fasted-FedDrug

    For Cohort FE-1, administration of a single dose of IPG1094 would occur on Day 1 of Period 1 under the fasted condition, and Day 5 (anticipated) of Period 2 under the fed condition.

  • IPG1094 100 mg SADDrug

    a Single-dose Treatment Period of 1 day, and a Follow-up period of 7 days,100 mg, QD, 1 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Part A (SAD):From signed ICF up to D8;Part B (MAD):From signed ICF up to D17;Part C (MAD):From signed ICF up to D17;Part D (FE):From signed ICF up to D12;

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.